Published in Science on June 18, 1993
Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev (1998) 8.51
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J (1998) 7.15
Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature (2008) 5.38
A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J (1996) 3.40
Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci U S A (1996) 2.70
Multiple myeloma: increasing evidence for a multistep transformation process. Blood (1998) 2.29
Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation? Ann Surg (1996) 2.24
Hepatic acute-phase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function. J Exp Med (2010) 2.17
Differentiation and growth arrest signals are generated through the cytoplasmic region of gp130 that is essential for Stat3 activation. EMBO J (1996) 2.07
Transient cytokine treatment induces acinar cell reprogramming and regenerates functional beta cell mass in diabetic mice. Nat Biotechnol (2013) 2.06
Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci U S A (1995) 2.05
Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov (2012) 1.91
A critical cytoplasmic domain of the interleukin-5 (IL-5) receptor alpha chain and its function in IL-5-mediated growth signal transduction. Mol Cell Biol (1994) 1.77
Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130. Proc Natl Acad Sci U S A (1994) 1.74
The signalling pathways of interleukin-6 and gamma interferon converge by the activation of different transcription factors which bind to common responsive DNA elements. Mol Cell Biol (1994) 1.70
Cloning of a murine IL-11 receptor alpha-chain; requirement for gp130 for high affinity binding and signal transduction. EMBO J (1994) 1.70
The interleukin-6-activated acute-phase response factor is antigenically and functionally related to members of the signal transducer and activator of transcription (STAT) family. Mol Cell Biol (1994) 1.67
STAT3 activation by cytokines utilizing gp130 and related transducers involves a secondary modification requiring an H7-sensitive kinase. Proc Natl Acad Sci U S A (1995) 1.65
Interleukin-6: structure-function relationships. Protein Sci (1997) 1.59
Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis (2000) 1.56
Sympathetic neurons can produce and respond to interleukin 6. Proc Natl Acad Sci U S A (1998) 1.51
Activation and inhibition of erythropoietin receptor function: role of receptor dimerization. Mol Cell Biol (1994) 1.47
Rheumatoid and pyrophosphate arthritis synovial fibroblasts induce osteoclastogenesis independently of RANKL, TNF and IL-6. J Autoimmun (2012) 1.43
Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signalling. EMBO J (1995) 1.39
Novel neurotrophin-1/B cell-stimulating factor-3: a cytokine of the IL-6 family. Proc Natl Acad Sci U S A (1999) 1.34
Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res (2009) 1.32
c-Cbl-dependent monoubiquitination and lysosomal degradation of gp130. Mol Cell Biol (2008) 1.31
1.9 A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling. EMBO J (1997) 1.30
Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression. Biochem J (1998) 1.28
Functional and biochemical association of Hck with the LIF/IL-6 receptor signal transducing subunit gp130 in embryonic stem cells. EMBO J (1994) 1.27
Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int J Biol Sci (2012) 1.27
IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol (2014) 1.27
Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol (2009) 1.26
Identification of a nonsense mutation in the granulocyte-colony-stimulating factor receptor in severe congenital neutropenia. Proc Natl Acad Sci U S A (1994) 1.25
gp130 and c-Kit signalings synergize for ex vivo expansion of human primitive hemopoietic progenitor cells. Proc Natl Acad Sci U S A (1995) 1.24
Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization. Am J Pathol (2007) 1.23
Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag Res (2011) 1.23
Crystal structure of a cytokine-binding region of gp130. EMBO J (1998) 1.23
Multiple regions within the cytoplasmic domains of the leukemia inhibitory factor receptor and gp130 cooperate in signal transduction in hepatic and neuronal cells. Mol Cell Biol (1994) 1.20
Proliferative responses and binding properties of hematopoietic cells transfected with low-affinity receptors for leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor. Proc Natl Acad Sci U S A (1994) 1.19
Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3. Immunology (2007) 1.10
Generation of interleukin-6 receptor antagonists by molecular-modeling guided mutagenesis of residues important for gp130 activation. EMBO J (1994) 1.10
Analysis of interleukin 6 receptor and gp130 expressions and proliferative capability of human CD34+ cells. J Exp Med (1996) 1.10
Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation. Front Immunol (2014) 1.10
Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells. Br J Pharmacol (2010) 1.07
Central exercise action increases the AMPK and mTOR response to leptin. PLoS One (2008) 1.05
Structure-function analysis of human IL-6: identification of two distinct regions that are important for receptor binding. Protein Sci (1994) 1.04
Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Mol Cancer Ther (2009) 1.02
Activation of the signal transducer gp130 by interleukin-11 and interleukin-6 is mediated by similar molecular interactions. Biochem J (1998) 1.02
The soluble interleukin-6 receptor is a mediator of hematopoietic and skeletal actions of parathyroid hormone. J Biol Chem (2013) 1.00
Crystal structure of the entire ectodomain of gp130: insights into the molecular assembly of the tall cytokine receptor complexes. J Biol Chem (2010) 0.99
Interleukin-6-induced STAT3 transactivation and Ser727 phosphorylation involves Vav, Rac-1 and the kinase SEK-1/MKK-4 as signal transduction components. Biochem J (2000) 0.99
Development of an interleukin (IL) 6 receptor antagonist that inhibits IL-6-dependent growth of human myeloma cells. J Exp Med (1994) 0.99
Phosphorylation and internalization of gp130 occur after IL-6 activation of Jak2 kinase in hepatocytes. Mol Biol Cell (1994) 0.99
Mediation of interleukin-11-dependent biological responses by a soluble form of the interleukin-11 receptor. Biochem J (1996) 0.99
The role of the inhibitors of interleukin-6 signal transduction SHP2 and SOCS3 for desensitization of interleukin-6 signalling. Biochem J (2004) 0.98
Internalization of the interleukin 6 signal transducer gp130 does not require activation of the Jak/STAT pathway. Biochem J (1998) 0.97
Blockade of IL-6 Trans signaling attenuates pulmonary fibrosis. J Immunol (2014) 0.97
Impairment of antigen-specific antibody production in transgenic mice expressing a dominant-negative form of gp130. Proc Natl Acad Sci U S A (1997) 0.97
Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis. Core Evid (2010) 0.96
Ciliary neurotrophic factor stimulates muscle glucose uptake by a PI3-kinase-dependent pathway that is impaired with obesity. Diabetes (2009) 0.96
Sequestration and scavenging of iron in infection. Infect Immun (2013) 0.95
Ligand-specific utilization of the extracellular membrane-proximal region of the gp130-related signalling receptors. Biochem J (2000) 0.95
Rational design of a receptor super-antagonist of human interleukin-6. EMBO J (1994) 0.94
Flagellar adhesion-dependent regulation of Chlamydomonas adenylyl cyclase in vitro: a possible role for protein kinases in sexual signaling. J Cell Biol (1994) 0.94
Interleukin-6 attenuates agonist-mediated calcium mobilization in murine osteoblastic cells. J Clin Invest (1994) 0.93
Imbalanced gp130-dependent signaling in macrophages alters macrophage colony-stimulating factor responsiveness via regulation of c-fms expression. Mol Cell Biol (2004) 0.91
Viral interleukin-6: role in Kaposi's sarcoma-associated herpesvirus: associated malignancies. J Interferon Cytokine Res (2011) 0.89
Cytokine-dependent gp130 receptor subunit regulates human fetal pituitary adrenocorticotropin hormone and growth hormone secretion. J Clin Invest (1997) 0.89
E-cadherin distribution in interleukin 6-induced cell-cell separation of ductal breast carcinoma cells. Proc Natl Acad Sci U S A (1994) 0.89
Interleukin-13 is a potent activator of JAK3 and STAT6 in cells expressing interleukin-2 receptor-gamma and interleukin-4 receptor-alpha. Biochem J (1996) 0.89
Cytokines and their receptors in cardiovascular diseases--role of gp130 signalling pathway in cardiac myocyte growth and maintenance. Int J Exp Pathol (2000) 0.89
Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells. J Exp Med (1995) 0.88
Identification and characterization of an alternative cytotoxic T lymphocyte-associated protein 4 binding molecule on B cells. Proc Natl Acad Sci U S A (1996) 0.87
Human interleukin-3 (IL-3) induces disulfide-linked IL-3 receptor alpha- and beta-chain heterodimerization, which is required for receptor activation but not high-affinity binding. Mol Cell Biol (1996) 0.87
Prevention of methamphetamine-induced microglial cell death by TNF-α and IL-6 through activation of the JAK-STAT pathway. J Neuroinflammation (2012) 0.86
Phosphorylation of the human leukemia inhibitory factor (LIF) receptor by mitogen-activated protein kinase and the regulation of LIF receptor function by heterologous receptor activation. Proc Natl Acad Sci U S A (1995) 0.86
Suppression of bone resorption by madindoline A, a novel nonpeptide antagonist to gp130. Proc Natl Acad Sci U S A (2002) 0.85
Oncostatin M induced alpha1-antitrypsin (AAT) gene expression in Hep G2 cells is mediated by a 3' enhancer. Biochem J (2002) 0.85
Hepatocyte and immune system: acute phase reaction as a contribution to early defence mechanisms. Gut (1994) 0.83
Leptin-Induced JAK/STAT Signaling and Cancer Growth. Vaccines (Basel) (2016) 0.82
The JAK-STAT pathway in hypertrophic stress signaling and genomic stress response. JAKSTAT (2012) 0.82
Involvement of Stat3 in interleukin-6-induced IgM production in a human B-cell line. Immunology (1997) 0.82
The beta subunit of human granulocyte-macrophage colony-stimulating factor receptor forms a homodimer and is activated via association with the alpha subunit. J Exp Med (1996) 0.81
Diagnostic and Prognostic Value of Serum Interleukin-6 in Colorectal Cancer. Medicine (Baltimore) (2016) 0.80
Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther Adv Musculoskelet Dis (2012) 0.80
Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity. EMBO J (1996) 0.79
Differential regulation of the expression of interleukin-2 receptor gamma-chain during the in vitro differentiation of human myeloid cells. Biochem J (1995) 0.79
The adaptor protein TRAF3 inhibits interleukin-6 receptor signaling in B cells to limit plasma cell development. Sci Signal (2015) 0.79
Constitutive activation of a variant of the env-mpl oncogene product by disulfide-linked homodimerization. J Virol (1995) 0.79
The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis. Clin Exp Immunol (2017) 0.79
Lnk adaptor suppresses radiation resistance and radiation-induced B-cell malignancies by inhibiting IL-11 signaling. Proc Natl Acad Sci U S A (2013) 0.78
Ubiquitin-mediated regulation of JAK-STAT signaling in embryonic stem cells. JAKSTAT (2012) 0.78
Diet-induced obesity and ethanol impair progression of hepatocellular carcinoma in a mouse mesenteric vein injection model. Surg Endosc (2012) 0.78
Targeting oligodendrocyte protection and remyelination in multiple sclerosis. Mt Sinai J Med (2011) 0.78
Revisiting the role of erythropoietin for treatment of ocular disorders. Eye (Lond) (2016) 0.77
Promoting myelin repair and return of function in multiple sclerosis. FEBS Lett (2011) 0.77
Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell (1997) 18.91
JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell (1994) 16.30
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A (1998) 12.61
Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature (1996) 10.67
Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm (1978) 10.01
Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature (1986) 9.63
A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J (1990) 9.17
Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature (1994) 8.85
Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci U S A (1998) 7.69
The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature (1998) 7.38
Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A (1997) 7.08
mRNA polyadenylate-binding protein: gene isolation and sequencing and identification of a ribonucleoprotein consensus sequence. Mol Cell Biol (1986) 7.07
Essential role of Stat6 in IL-4 signalling. Nature (1996) 6.56
Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell (1994) 6.45
The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity (1994) 6.18
Structure and function of a new STAT-induced STAT inhibitor. Nature (1997) 6.02
On the coronary circulation in the heart-lung preparation. J Physiol (1922) 5.97
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell (1989) 5.72
Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci U S A (1987) 5.68
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature (1988) 5.60
Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene (2000) 5.39
Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol (1997) 5.38
Superconductivity at 39 K in magnesium diboride. Nature (2001) 5.20
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum (2006) 5.20
Biological and clinical aspects of interleukin 6. Immunol Today (1990) 5.17
Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J (1990) 5.16
Cytokine signal transduction. Cell (1994) 5.14
Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell (1990) 5.06
Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med (2000) 5.02
Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science (1988) 4.93
Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene (2010) 4.81
Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J Immunol (1998) 4.74
A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn (1981) 4.73
Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity (1998) 4.70
Synergistic signaling in fetal brain by STAT3-Smad1 complex bridged by p300. Science (1999) 4.69
Interleukin-6 family of cytokines and gp130. Blood (1995) 4.52
Defective adipocyte differentiation in mice lacking the C/EBPbeta and/or C/EBPdelta gene. EMBO J (1997) 4.51
JNK is involved in signal integration during costimulation of T lymphocytes. Cell (1994) 4.36
Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. Cell (1995) 4.34
The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med (1988) 4.31
Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology (1998) 4.29
Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci U S A (1994) 4.25
Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science (1994) 4.24
Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci U S A (1993) 4.23
Kinesin superfamily motor protein KIF17 and mLin-10 in NMDA receptor-containing vesicle transport. Science (2000) 4.14
Interleukin-6 in biology and medicine. Adv Immunol (1993) 4.06
IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A (1989) 4.03
Predictive factors of response to intravenous ciclosporin in severe ulcerative colitis: the development of a novel prediction formula. Aliment Pharmacol Ther (2012) 3.91
Infection with HIV is associated with elevated IL-6 levels and production. J Immunol (1990) 3.89
Regulation of human interleukin-2 gene: functional DNA sequences in the 5' flanking region for the gene expression in activated T lymphocytes. Cell (1986) 3.88
Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity (1996) 3.66
Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J (1987) 3.64
Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc Natl Acad Sci U S A (1993) 3.59
c-Jun can recruit JNK to phosphorylate dimerization partners via specific docking interactions. Cell (1996) 3.54
Interleukin-6 and its receptor: a paradigm for cytokines. Science (1992) 3.51
Interferon-beta gene regulation: tandemly repeated sequences of a synthetic 6 bp oligomer function as a virus-inducible enhancer. Cell (1987) 3.51
Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta. Cell (2001) 3.49
Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci U S A (1985) 3.46
A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J (1996) 3.40
Maturational disturbance of chondrocytes in Cbfa1-deficient mice. Dev Dyn (1999) 3.33
Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family. Proc Natl Acad Sci U S A (1991) 3.31
Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A (1993) 3.29
Interleukins and IgA synthesis. Human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells. J Exp Med (1989) 3.28
Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm (1978) 3.27
IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol (2000) 3.08
Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J Immunol (1989) 3.01
Analysis of upstream elements in the HuC promoter leads to the establishment of transgenic zebrafish with fluorescent neurons. Dev Biol (2000) 2.93
LIFR beta and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor. Science (1993) 2.93
DNA methylation is a critical cell-intrinsic determinant of astrocyte differentiation in the fetal brain. Dev Cell (2001) 2.90
Intestinal lymphangiectasia markedly improved with antiplasmin therapy. Gastroenterology (1989) 2.88
B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med (1988) 2.88
Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res (1996) 2.86
CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130. Cell (1992) 2.83
IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol Rev (1992) 2.80
AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci U S A (1990) 2.79
Dynamics of centromeres during metaphase-anaphase transition in fission yeast: Dis1 is implicated in force balance in metaphase bipolar spindle. Mol Biol Cell (1998) 2.79
Factors affecting B-cell growth and differentiation. Annu Rev Immunol (1985) 2.78
Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc Natl Acad Sci U S A (1987) 2.76